Economic evaluation of options for measles vaccination strategy in a hypothetical Western European country

Epidemiology and Infection

Volumn 130, Issue 2, 2003, Pages 273-283

  Beutels, Ph ^a   Gay, N J ^b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MEASLES VACCINE;

ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; INFECTION SENSITIVITY; LIFE EXPECTANCY; MEASLES; MEASLES VACCINATION; SENSITIVITY ANALYSIS; WESTERN EUROPE;

COST OF ILLNESS; COST-BENEFIT ANALYSIS; EUROPE; HUMANS; INFANT; MEASLES VACCINE; VACCINATION;

EID: 0037398371     PISSN: 09502688     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0950268802008142     Document Type: Article

References (29)

1. Gay NJ, Pelletier L, Duclos P. Modelling the incidence of measles in Canada: an assessment of the options for vaccination policy. Vaccine 1998; 16: 794-801.
2. Babad HR, Nokes DJ, Gay NJ, Miller E, Morgan-Capner P, Anderson RM. Predicting the impact of measles vaccination in England and Wales: model validation and analysis of policy options. Epidemiol Infect 1995; 114: 319-44.
3. Koopmanschap MA, Rutten FFH. Indirect costs in economic studies: confronting the confusion. PharmacoEconomics 1993; 4: 446-54.
4. Brouwer WBF, Koopmanschap MA. How to calculate indirect costs in economic evaluations: correspondence. PharmacoEconomics 1998; 13: 563-9.
5. Liljas B. How to calculate indirect costs in economic evaluations: the author's reply. PharmacoEconomics 1998; 13: 566-96.
6. Olsen JA, Smith RD. Theory versus practice: a review of 'willingness to pay' in health and health care. Health Econ 2001; 10: 39-52.
7. Neuhauser D, Lweicki AM. What do we gain from the sixth stool guaiac? N Engl J Med 1975; 293: 226-8.
8. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russel LB for the panel on Cost-Effectiveness in Health and Medicine. Recommendations of the panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276: 1253-8.
9. De Serres G, Boulianne N, Meyer F, Ward BJ. Measles vaccine efficacy during an outbreak in a highly vaccinated population: incremental increase in protection with age at vaccination up to 18 months. Epidemiol Infect 1995; 115: 315-23.
10. Fine PE, Zell ER. Outbreaks in highly vaccinated populations: implications for studies of vaccine performance. Am J Epidemiol 1994; 139: 77-90.
11. Miller CL. Severity of notified measles. BMJ 1978; 1: 1253-5.
12. Miller C, Farrington CP, Harbert K. The epidemiology of subacute sclerosing panencephalitis in England and Wales 1970-1989. Int J Epidemiol 1992; 21: 998-1006.
13. Ramsay M, Gay N, Miller E, Rush M. White J, Morgan-Capner P, Brown D. The epidemiology of measles in England and Wales: rationale for the 1994 national vaccination campaign. CDR Rev 1994; 4: R141-6.
14. Gindler JS, Atkinson WL, Markowitz LE, Hutchins SS. Epidemiology of measles in the United States in 1989 and 1990. Pediatr Infect Dis J 1992; 11: 841-6.
15. Godoy P, Dominguez A, Alvarez J, et al. Measles epidemiology in Catalonia (Spain): implications for a regional vaccination programme. Int J Epidemiol 1999; 28: 558-62.
16. Baron S, Pulvenis D, Turco E. Investigation d'une epidemic dc rougeole en Indre et Loire (mars 1995). Rev d'Epidemiol Santé Publique 1996; 44: S19.
17. Atkinson WL, Kaplan JM, Clover R. Measles: virology, epidemiology, disease, and prevention. Am J Prev Med 1994; 10 (Suppl): 22-30.
18. Ruggenini AM, Zotti C, Pedronetto A, Milano R, Garella D, Sacchetti C. I Ricoveri ospedalieri in Torino per morbillo e relative complicanze, nel periodo 1973-1983: valutazioni sanitarie ed economiche, in rapporto alla opportunità dell'intervento vaccinale. Boll Ist Sieroter Milan 1986; 65: 502-11.
19. McConnell WW, Tohani VK. Measles in the Southern Health Board - implications for resources. BMJ (Clin Res Ed) 1984; 289: 293-6.
20. Mansoor O, Blakely T, Baker M, Tobias M, Bloomfield A. A measles epidemic controlled by immunisation. N Z Med J 1998; 111: 467-71.
21. Taracena del Pinal B, Monton JL, Cristobal P, Gonzalez F, Casas J. Contribución al estudio de costos del sarampión en España. An Esp Pediatr 1983; 19: 383-8.
22. Beutels P, Van Damme P, Van Casteren V, Gay NJ, De Schrijver K, Meheus A. The difficult quest for data on 'vanishing' vaccine-preven table infections in Europe: the case of measles in Flanders (Belgium). Vaccine 2002; 20: 3551-9.
23. Beutels P, Van Damme P, Van Doorslaer E. Program evaluation of universal varicella vaccination in Belgium: preliminary results. ESOC 2000, Report No. 36.
24. Coudeville L, Paree F, Lebrun T, Sailly J. The value of varicella vaccination in healthy children: cost-benefit analysis of the situation in France. Vaccine 1999; 17: 142-51.
25. Beutels P, Clara R, Tormans G, Van Doorslaer E, Van Damme P. Costs and benefits of routine varicella vaccination in German children. J Infect Dis 1996; 174 (Suppl 3): S335-41.
26. Diez Domingo J, Ridao M, Latour J, Ballester A, Morant A. A cost benefit analysis of routine varicella vaccination in Spain. Vaccine 1999; 17: 1306-11.
27. Goldman L, Gordon D, Rifkind B, et al. Cost and health implications of cholesterol lowering. Circulation 1992; 85: 1960-8.
28. Meltzer D. Accounting for future costs in medical cost-effectiveness analysis. J Health Econ 1997; 16: 33-64.
29. Beutels P. Economic evaluation of vaccination programmes in humans: a methodological exploration with applications to hepatitis B, varicella-zoster, measles, pertussis, hepatitis A and pneumococcal vaccination. University of Antwerp, 2002.